Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cocktail aims to tame aggressive lymphoma in the very elderly

NCT ID NCT04974216

Ongoing Disease control Sponsor: The Lymphoma Academic Research Organisation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a combination of three drugs—tafasitamab, lenalidomide, and rituximab—in people aged 80 and older with untreated diffuse large B-cell lymphoma (DLBCL). The goal is to see if this gentler, chemotherapy-free regimen can shrink or eliminate tumors after three cycles of treatment. The study enrolled 71 participants and is no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tafasitamab, lenalidomide, and rituximab
What this could lead to
If successful, this combination could offer a gentler, effective treatment option for elderly patients with diffuse large B-cell lymphoma who cannot tolerate standard chemotherapy.
What could go wrong
This is a small, early-phase trial (71 patients) with no comparison group. The drugs may cause serious side effects, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DLBCL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma high grade B-cell lymphoma high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DLBCL

Contacts and locations

Locations

  • APHP - Hôpital Saint Louis

    Paris, France

  • Besancon University Hospital Center

    Besançon, 25030, France

  • CH Saint Vincent de Paul

    Lille, France

  • CHRU Mont Godinne

    Yvoir, Belgium

  • CHRU de LILLE - Claude Huriez

    Lille, France

  • CHU Brabois

    Vandœuvre-lès-Nancy, France

  • CHU Helora

    La Louvière, 7100, Belgium

  • CHU de Bordeaux - Hôpital Haut Lévêque

    Bordeaux, France

  • CHU de Liège

    Liège, Belgium

  • CHU de Nantes - Hôtel Dieu

    Nantes, France

  • Centre Henri Becquerel

    Rouen, France

  • Centre Hospitalier D Avignon

    Avignon, France

  • Centre Hospitalier De La Cote Basque

    Bayonne, France

  • Centre Hospitalier Departemental Vendee

    La Roche-sur-Yon, France

  • Centre Hospitalier Sud Francilien

    Corbeil-Essonnes, France

  • Chu de Limoges - Hopital Dupuytren

    Limoges, France

  • Clinique Universitaire Saint LUC

    Brussels, Belgium

  • Grand Hopital De Charleroi

    Charleroi, 6000, Belgium

  • Institut Bergonié - Bordeaux

    Bordeaux, France

  • Institut de Cancérologie de la Loire Lucien Neuwirth

    Saint-Priest-en-Jarez, 42270, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.